Evaluation of a Decision Analysis Model in the DASH-Osteo Decision Aid.
NCT07120854 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 114
Last updated 2025-08-13
Summary
Fragility fractures, often caused by low bone mineral density, are a major health concern for postmenopausal women. One way to prevent these fractures is by taking medication, but deciding whether to start treatment can be difficult due to potential risks and side effects.
This study will test a web-based tool designed to help women make informed decisions about fracture prevention treatment. The tool provides information about the benefits and risks of treatment. Some women in the study will also receive additional support through a decision analysis report, which helps weigh different factors when making a choice.
The study will examine whether using this tool improves decision-making, increases confidence in making a choice, and enhances satisfaction with the decision. It will also explore what factors influence women's decisions and at what level of risk they choose to start treatment.
By understanding how decision aids impact choices, researchers aim to improve the way healthcare providers support patients in making informed decisions about their health.
Conditions
- Osteoporosis, Postmenopausal
- Osteoporotic Fractures
- Diphosphonates
- Fracture Risk Assessment
Interventions
- OTHER
-
Decision aid with decision analysis model
Women will use the web version of the decision aid tool. They will have a supporting video to help them how to navigate the tool during. They will be able to access the tool through a specific link that will be shared with them by their central research team via e-mail. Each woman is expected to use the web tool and select her preferences (utilities) regarding different health conditions (e.g. hip fracture). The results of the exercises will be received automatically at the central level (by institutional e-mail to the researcher responsible for the data a PDF file will be sent from the web). The research team at the central level will apply the decision analysis model, using information on the baseline fracture risk and preferences of each participant entered into the tool. The results of the decision analysis model will be delivered to the women directly by e-mail in plain language, so that they can make the final decision together with their general practitioner in a second visit.
- OTHER
-
Decision aid alone
Participants will use the web tool. They will have a supporting video to help them how to navigate the tool during. They will be able to access the tool through a specific link that will be shared with them by the central research team via e-mail. Each woman is expected to navigate through the different functions of the web tool, at home or at a time other than the medical visit, and select her preferences (utilities) with respect to different health conditions (e.g. hip fracture). The women in this group would decide whether or not to take the pharmacological treatment based on the information provided by the tool but without the results of the decision analysis model described for the intervention group. Subsequently, those who wished to do so would make a final decision together with their physician at a second visit.
- OTHER
-
Usual Care
Women in this group will receive standard clinical practice, without the use of the shared decision support tool or the decision analysis model or any other support. At the end of the visit, their physician will provide them with a link to access the assessment questionnaires.
Sponsors & Collaborators
-
Institut Catala de Salut
collaborator OTHER_GOV -
Servicio Madrileño de Salud, Madrid, Spain
collaborator OTHER -
Fondo de Investigacion Sanitaria
collaborator OTHER -
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-04-03
- Primary Completion
- 2025-12-20
- Completion
- 2026-02-25
Countries
- Spain
Study Locations
More Related Trials
-
StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
NCT06767150 ·Status: RECRUITING ·Phase: PHASE4
-
Osteoporosis Treatment in Post-menopausal Women
NCT03006003 ·Status: UNKNOWN ·Phase: PHASE4
-
Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication
NCT02472782 ·Status: COMPLETED
-
Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
NCT01753856 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of PTH(1-34) Treatment on Fracture Healing in Vivo
NCT00741182 ·Status: WITHDRAWN ·Phase: PHASE2
-
Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
NCT00680953 ·Status: COMPLETED ·Phase: PHASE3
-
STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)
NCT00583518 ·Status: COMPLETED ·Phase: PHASE4
-
Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
NCT00136058 ·Status: COMPLETED ·Phase: PHASE3
-
Activity of Pre-Osteoclasts and Osteoclasts Over Time in Postmenopausal Women Treated With Denosumab or Zoledronic Acid
NCT03812367 ·Status: WITHDRAWN
-
Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects
NCT00666627 ·Status: COMPLETED ·Phase: PHASE2
-
MAGnesium Effect With ANtiosteoporotic Drugs
NCT05328154 ·Status: COMPLETED ·Phase: PHASE2
-
Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
NCT02155595 ·Status: COMPLETED
-
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
NCT00330460 ·Status: COMPLETED ·Phase: PHASE3
-
A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
NCT00887354 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)
NCT00713258 ·Status: TERMINATED ·Phase: PHASE4
-
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
NCT00205777 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates
NCT00936897 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)
NCT01803607 ·Status: TERMINATED ·Phase: PHASE3
-
Bisphosphonates for Prevention of Post-Denosumab Bone Loss
NCT03396315 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
NCT00729183 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
NCT01732770 ·Status: COMPLETED ·Phase: PHASE4
-
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
NCT07242612 ·Status: RECRUITING ·Phase: NA
-
Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia
NCT05386784 ·Status: COMPLETED ·Phase: PHASE4
-
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
NCT00383422 ·Status: COMPLETED ·Phase: PHASE3
-
Secondary Prevention of Osteoporosis
NCT00421343 ·Status: COMPLETED ·Phase: PHASE3